TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher is investigating traditional medicinal plants to identify
compounds that may have therapeutic effects. Which feature of
historical plant-based drug discovery best explains its importance to
modern pharmacology?
A. It provided empirical observations of biologically active substances
before molecular mechanisms were understood.
,B. It eliminated the need for chemical purification of active compounds.
C. It ensured that discovered substances had predictable
pharmacokinetics.
D. It allowed therapeutic compounds to bypass formal drug
development.
Correct Answer:
A. It provided empirical observations of biologically active substances
before molecular mechanisms were understood.
Rationale:
A is correct because early drug discovery frequently relied on observed
biological effects of plants and other natural materials before the
responsible molecular targets or mechanisms were known. This
empirical approach generated important starting points for later
isolation, characterization, and optimization of active compounds.
B is incorrect because active compounds often had to be isolated and
characterized to determine which constituents produced the observed
effects.
C is incorrect because historical discovery did not guarantee favorable
absorption, distribution, metabolism, or elimination.
D is incorrect because promising natural substances still require
systematic evaluation before therapeutic use.
Question 2
A medicinal chemistry team identifies a naturally occurring molecule
with measurable activity against a disease-relevant biological system,
but the molecule has poor selectivity and other unfavorable properties.
What is the best description of this molecule at this stage?
, A. Approved therapeutic agent
B. Lead compound
C. Biosimilar
D. Final formulation
Correct Answer:
B. Lead compound
Rationale:
B is correct because a lead compound is a biologically active starting
point that can be chemically modified to improve properties such as
potency, selectivity, and suitability for development.
A is incorrect because biological activity alone does not constitute
regulatory approval.
C is incorrect because a biosimilar is a biological product developed to
be highly similar to an already approved biologic.
D is incorrect because formulation is a later development consideration
rather than the definition of a lead compound.
Question 3
Researchers systematically change different portions of a candidate
molecule and compare the resulting changes in biological activity. What
principle are they primarily investigating?
A. Structure–activity relationship
B. Postmarketing surveillance
C. Clinical randomization
D. Therapeutic equivalence
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher is investigating traditional medicinal plants to identify
compounds that may have therapeutic effects. Which feature of
historical plant-based drug discovery best explains its importance to
modern pharmacology?
A. It provided empirical observations of biologically active substances
before molecular mechanisms were understood.
,B. It eliminated the need for chemical purification of active compounds.
C. It ensured that discovered substances had predictable
pharmacokinetics.
D. It allowed therapeutic compounds to bypass formal drug
development.
Correct Answer:
A. It provided empirical observations of biologically active substances
before molecular mechanisms were understood.
Rationale:
A is correct because early drug discovery frequently relied on observed
biological effects of plants and other natural materials before the
responsible molecular targets or mechanisms were known. This
empirical approach generated important starting points for later
isolation, characterization, and optimization of active compounds.
B is incorrect because active compounds often had to be isolated and
characterized to determine which constituents produced the observed
effects.
C is incorrect because historical discovery did not guarantee favorable
absorption, distribution, metabolism, or elimination.
D is incorrect because promising natural substances still require
systematic evaluation before therapeutic use.
Question 2
A medicinal chemistry team identifies a naturally occurring molecule
with measurable activity against a disease-relevant biological system,
but the molecule has poor selectivity and other unfavorable properties.
What is the best description of this molecule at this stage?
, A. Approved therapeutic agent
B. Lead compound
C. Biosimilar
D. Final formulation
Correct Answer:
B. Lead compound
Rationale:
B is correct because a lead compound is a biologically active starting
point that can be chemically modified to improve properties such as
potency, selectivity, and suitability for development.
A is incorrect because biological activity alone does not constitute
regulatory approval.
C is incorrect because a biosimilar is a biological product developed to
be highly similar to an already approved biologic.
D is incorrect because formulation is a later development consideration
rather than the definition of a lead compound.
Question 3
Researchers systematically change different portions of a candidate
molecule and compare the resulting changes in biological activity. What
principle are they primarily investigating?
A. Structure–activity relationship
B. Postmarketing surveillance
C. Clinical randomization
D. Therapeutic equivalence
